Merus N.V. announced that it has entered into the Collaboration Agreement, pursuant to the Subscription Agreement with new investor, Gilead Sciences, Inc. that the company has issued 452,527 common shares at a price per share of $55.2454 for aggregate gross proceeds of $25,000,035 on March 5, 2024. Gilead Sciences, Inc. agreed to transfer, sell, or otherwise dispose of the Shares for a period of time following the purchase of the Shares, subject to certain customary exceptions. The Shares were issued in reliance upon an exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.77 USD | -2.36% | -8.13% | +62.80% |
May. 13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
May. 13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
67.65 USD | +0.16% | +3.35% | 84.28B | ||
44.77 USD | -2.36% | -8.13% | 2.63B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.80% | 2.63B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.